- Trials with a EudraCT protocol (323)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
323 result(s) found for: Genetic association.
Displaying page 1 of 17.
EudraCT Number: 2013-003938-32 | Sponsor Protocol Number: 11190801 | Start Date*: 2014-02-12 |
Sponsor Name:Medizinische Universität Graz | ||
Full Title: Genetic alterations in genes coding for transporters and metformin resistance | ||
Medical condition: We want to investigate the pharmacokintetics of metformin in patients with type 2 diabetes or polycystic ovary syndrome in association with the patients genotype | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000106-31 | Sponsor Protocol Number: 2958 | Start Date*: 2005-03-15 |
Sponsor Name:Royal Liverpool University Hospital Clinical Trials 4th floor Linda McCartney Centre | ||
Full Title: IMPACT OF CYP2D6, SEROTONIN TRANSPORTER, 5HT1, 5HT2 AND 5HT3 RECEPTOR AND MU RECEPTOR GENE POLYMORPHISMS ON EFFICACY AND TOXICITY OF TRAMADOL | ||
Medical condition: OSTEOPOROSIS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003559-21 | Sponsor Protocol Number: CDEB025A2212 | Start Date*: 2012-02-28 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin | |||||||||||||
Medical condition: Hepatitis C and how biomarkers affect the response to treatment of the disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005756-37 | Sponsor Protocol Number: CONTENTSS | Start Date*: 2021-11-02 | ||||||||||||||||
Sponsor Name:Fundación Pública Andaluza para la Gestión de la | ||||||||||||||||||
Full Title: Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock | ||||||||||||||||||
Medical condition: Patients with septic shock who remain without reaching the hemodynamic goal of TAM> 65 mmHg, despite volume replacement and administration of noradrenaline at doses equal to or greater than 0.2 μg ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003425-81 | Sponsor Protocol Number: RLBUHT2763 | Start Date*: 2007-03-29 |
Sponsor Name:University of Liverpool | ||
Full Title: Host genetic factors influencing drug disposition and response to HIV treatment | ||
Medical condition: Pharmacogeneric study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification will... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004874-42 | Sponsor Protocol Number: TRAFO001 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:Institut für Frauengesundheit GmbH | |||||||||||||
Full Title: Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen M... | |||||||||||||
Medical condition: The study examines the influence of pharmacogenetic markers on the efficacy and side effects in postmenopausal, steroid hormone positive breast cancer patients, who are treated with Letrozol. The p... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015502-19 | Sponsor Protocol Number: EMR200136_022 | Start Date*: 2009-12-14 | |||||||||||
Sponsor Name:Merck Serono SA – Geneva | |||||||||||||
Full Title: A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Mu... | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) DE (Completed) BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004114-99 | Sponsor Protocol Number: FERTIRES-2016 | Start Date*: 2017-05-18 |
Sponsor Name:AB-BIOTICS | ||
Full Title: USE OF P.N680S POLYMORPHISM TO CHOOSE THE EXOGEN FSH DOSE IN CONTROLLED OVARIAN HYPERSTIMULATION: A PROSPECTIVE TRIAL | ||
Medical condition: Infertility | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006076-38 | Sponsor Protocol Number: RLBUHT3173 | Start Date*: 2007-04-26 |
Sponsor Name:University of Liverpool
[...]
1. University of Liverpool
2. Royal Liverpool & Broadgreen University Hospitals Trust |
||
Full Title: The Liverpool HIV TDM Registry: Studying influences upon plasma HIV drug exposure | ||
Medical condition: Pharmacogenetic study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification wil... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002649-19 | Sponsor Protocol Number: 7043 | Start Date*: 2010-04-07 |
Sponsor Name:Tartu University Hospital Psychiatry Clinic | ||
Full Title: Investigation of genetic predictors of the response to SSRI treatment in patients with panic disorder | ||
Medical condition: panic disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001777-25 | Sponsor Protocol Number: FILOCLL09-IDA53 | Start Date*: 2018-10-02 |
Sponsor Name:FILO | ||
Full Title: A Phase II Pilot Study to Evaluate the Safety and Efficacy of the association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with p53 dysfunction. IDA53 trial | ||
Medical condition: Relapsed/Refractory Chronic Lymphocytic Leukemia with p53 dysfunction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001534-11 | Sponsor Protocol Number: GIT-PRo-2022-02 | Start Date*: 2022-10-11 | ||||||||||||||||
Sponsor Name:Grupo Gallego de Investigación en Tumores Digestivos (GITuD) | ||||||||||||||||||
Full Title: Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line of treatment. | ||||||||||||||||||
Medical condition: Metastatic colorectal cancer (mCRC), stage IV that initiates the first-line systemic treatment in the metastatic setting | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003778-29 | Sponsor Protocol Number: CIFRA | Start Date*: 2019-03-06 |
Sponsor Name:Istituto Nazionale Tumori G. Pascale | ||
Full Title: Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / V | ||
Medical condition: advanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / V | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018559-84 | Sponsor Protocol Number: AMB-WEI-1052-I | Start Date*: 2010-07-20 | |||||||||||
Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen | |||||||||||||
Full Title: AMBITIOUS Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage Single- arm trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment i... | |||||||||||||
Medical condition: AMBITIOUS is a trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitis Atopische Dermatitis is a common inflammatory skin disea... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001258-82 | Sponsor Protocol Number: CFTRcysta1 | Start Date*: 2013-09-12 |
Sponsor Name:European Institute for Cystic Fibrosis Research (IERFC) | ||
Full Title: A phase II pilot clinical study of experimental research to evaluate the functional rescue of CFTR protein through proteostasis regulators | ||
Medical condition: Cystic fibrosis patients with F508del-CFTR in homozygous or compound heterozygous with Class I or II mutations | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003999-35 | Sponsor Protocol Number: Kep-F10.2.01 | Start Date*: 2007-01-11 |
Sponsor Name:Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie | ||
Full Title: Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients | ||
Medical condition: detoxified alcohol dependent outpatients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003835-31 | Sponsor Protocol Number: IB2018-04 | Start Date*: 2021-09-28 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study | |||||||||||||
Medical condition: Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020219-35 | Sponsor Protocol Number: | Start Date*: 2011-07-18 |
Sponsor Name:Royal Brompton & Harefield NHS Foundation Trust | ||
Full Title: Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI | ||
Medical condition: Cardiovascular disease - Acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015985-75 | Sponsor Protocol Number: HGT-REP-060 | Start Date*: 2010-02-03 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies (HGT), Inc. | |||||||||||||
Full Title: An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal Enzyme Replacement Therapy Administered to Adult Patients with Fabry Disease | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) CZ (Completed) GB (Completed) FI (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002731-32 | Sponsor Protocol Number: D/P3/21/7 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Diamyd Medical AB | |||||||||||||
Full Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with... | |||||||||||||
Medical condition: Type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) HU (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
